What Allay Therapeutics does

Allay Therapeutics is a clinical-stage biotechnology company developing ultra-sustained, non-opioid analgesic implants for post-surgical pain management. Founded in 2017 by The Foundry incubator and Lightstone Ventures' Singapore fund, the company is headquartered in San Jose, California (a 50,000 sq ft facility at BioSquare) with R&D operations in Singapore Science Park, and operates with a workforce of 11-50 employees. The platform is a proprietary drug-biopolymer architecture acquired via the 2018 purchase of Orchid Medical, which combines validated analgesics such as bupivacaine with Evonik-supplied biodegradable polymers to produce dissolvable implants that release drug over weeks rather than days, degrading into water and carbon dioxide after delivering therapeutic effect.

The lead candidate, ATX-101, is a small, coin-sized implant designed to be placed at the end of total knee arthroplasty (TKA) surgery in a simple "place-and-go" procedure, providing weeks of localized non-opioid pain relief. Clinical data from Phase 1b/2a and a dose-ranging Phase 2b trial (n=112) demonstrated up to 4 weeks of pain relief, a 50-66% reduction in opioid use, and an 80% opioid-free rate at 14 days versus approximately 50% for standard of care. ATX-101 received FDA Breakthrough Therapy Designation in December 2024, the Phase 2b registration trial (n=200) was initiated in February 2025, and Phase 3 is planned for 2026. The pipeline includes ATX-201 (new formulations), ATX-301 (injectable), ATX-401 (new indication), and ATX-501 (on-demand anesthetics delivery).

Allay is pre-revenue and has not yet commercialized a product. Its intended business model combines direct sales of ATX-101 to U.S. hospital systems and orthopedic centers for use in TKA procedures (an addressable market of over 1.2 million annual U.S. procedures and roughly $10 billion in total postsurgical-pain treatment spend) with licensing royalties and milestone payments from Maruishi Pharmaceutical, which holds exclusive rights to develop and commercialize ATX-101 in Japan and, as of June 2025, South Korea and Taiwan. The company has raised approximately $142.5 million across multiple venture rounds, including a $57.5 million Series D in June 2025 co-led by Lightstone Ventures and ClavystBio (Temasek's biotech platform).

Name

Allay Therapeutics

Legal name

Allay Therapeutics, Inc.

Website

https://allaytx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Allay Therapeutics is a clinical-stage biotechnology company developing ultra-sustained, non-opioid analgesic implants, with lead candidate ATX-101 targeting postsurgical pain in total knee arthroplasty patients. It is pre-revenue, serving future U.S. hospital customers directly and ex-U.S. markets via Maruishi Pharmaceutical.

Ownership category

akta.pro rank

Product category

Non-opioid analgesic therapeutics

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Ultra-sustained analgesics
• Non-opioid pain management
• Post-surgical therapeutics
• Drug-biopolymer implants
• Clinical-stage biotechnology

Headquarters

HQ city

San Jose

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (ATX101 and pipeline): Once approved, revenue will be generated from sales of ATX101 and other ultra-sustained analgesic products directly to healthcare providers and systems for post-surgical pain management. Target market includes total knee replacement surgeries performed in the United States, estimated at over 1.2 million procedures annually with a treatment market of approximately $10 billion.
2. Licensing Royalties (Japan): Development and commercialization agreement with Maruishi Pharmaceutical grants exclusive rights to develop and commercialize ATX101 in Japan. Allay receives upfront payments, equity investment, and is eligible for milestone payments and royalties on sales in Japan. Territory expanded to include South Korea and Taiwan.
3. Milestone Payments: Future milestone payments related to pre-defined clinical and regulatory events in the U.S. and Japan as well as commercial milestones under the Maruishi licensing agreement.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Allay Therapeutics develops ultra-sustained analgesic drug candidates that combine validated non-opioid analgesics (bupivacaine) with proprietary biodegradable polymers to create dissolvable implantable therapeutics. Its lead candidate ATX-101 is a small, coin-sized implant placed at the surgical site to deliver weeks of localized non-opioid pain relief after total knee arthroplasty. The platform is tunable across additional pain indications and surgical applications.

Product overview

Allay Therapeutics has developed a proprietary technology platform combining validated non-opioid analgesics (such as bupivacaine) and biodegradable polymers to create dissolvable drug delivery candidates. The platform enables tunable, ultra-sustained pain relief lasting weeks rather than days. The lead product ATX-101 is a small implant placed at the surgical site that provides continuous localized pain relief over weeks before dissolving. The pipeline includes ATX-201 (new formulations), ATX-301 (injectables), ATX-401 (new indication), and ATX-501 (on-demand delivery). The platform technology allows tuning of drug release profiles to match different pain patterns including post-surgical, chronic, and cyclic pain.

Differentiator

Problem solved

Functional benefit

Products and services

• ATX-101 Ultra-sustained analgesic implant combining bupivacaine with biodegradable polymers to provide weeks of localized non-opioid pain relief following total knee arthroplasty (TKA). Designed for simple 'place-and-go' administration at the surgical site, dissolving into water and carbon dioxide. Received FDA Breakthrough Therapy Designation in December 2024.
• ATX-201 New formulations in development based on Allay's ultra-sustained drug-biopolymer platform technology for extended pain management.
• ATX-301 Injectable formulation in development leveraging Allay's tunable drug-biopolymer architecture for pain relief applications.
• ATX-401 New clinical indication in development based on Allay's ultra-sustained analgesic platform.
• ATX-501 On-demand anesthetics delivery system in development, allowing patient self-administration of pain relief.

Quantifiable outcome

• Pain relief lasting at least 2 weeks (up to 4 weeks in dose-ranging trial) vs. 3 days maximum for current treatments
• +6 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship, minor and core.

• Maruishi PharmaceuticalflagshipStrategic or Co-development Partner · 18 December 2023License agreement providing Maruishi exclusive rights to develop and commercialize ATX101 and other ultra-sustained analgesic products in Japan. In June 2025, territory expanded to include South Korea and Taiwan. Maruishi is conducting Phase I/II multi-center open-label safety study of ATX101 in Japan. Allay received upfront payment, equity investment, and is eligible for milestone payments and royalties on sales.
• Renexes LLCminorOthers · 18 December 2023Served as advisor to Allay in connection with the Maruishi Pharmaceutical transaction.
• Cooley LLPminorOthers · 18 December 2023Acted as legal counsel to Allay for the Maruishi Pharmaceutical transaction.
• EvonikcoreTechnology or Integration · 13 December 2022Evonik invested in Allay Therapeutics and supplies biodegradable polymers that are a key component of the pain therapy implants. Evonik's polymers enable controlled drug delivery and the implant's dissolution in the body. Evonik has over 60 years of experience in targeted delivery technologies for medical agents through its Health Care Business Line.
• The FoundrycoreStrategic or Co-development Partner · 1 January 2017The Foundry incubator co-founded Allay Therapeutics in 2017 alongside Lightstone Ventures' Singapore fund. The Foundry shaped Allay's platform and vision.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Pacira BioSciences: Pacira is the leader in long-acting local anesthetics with Exparel (liposomal bupivacaine), directly competing with ATX-101 in post-surgical pain management. Both target the same orthopedic and soft-tissue surgery channels with sustained-release bupivacaine-based products, making Pacira the most direct comparable for commercialization dynamics.
• Heron Therapeutics: Heron developed HTX-011 (bupivacaine/meloxicam extended-release) for postsurgical pain, a direct mechanistic and indication competitor to ATX-101. Heron's experience navigating FDA review and orthopedic surgeon adoption provides a close analog for Allay's commercial path.
• Innocoll Pharmaceuticals: Innocoll developed XARACOLL, a bupivacaine collagen-matrix implant for postsurgical pain, making it a direct competitor using a drug-polymer/implant approach similar in concept to Allay's biopolymer platform. Closely comparable in technology modality and surgical-site deployment.

Emerging players

• Trevena: Trevena is a clinical-stage company developing acute pain therapeutics, including OLINVYK (oliceridine), targeting the same hospital/surgeon channel that ATX-101 will enter. Relevant as a comparable specialty pain-focused biotech pursuing postsurgical and acute pain markets.
• Cara Therapeutics: Cara Therapeutics commercialized KORSUVA (difelikefalin) for pruritus and is developing non-opioid pain assets targeting similar payor demand for opioid-sparing therapies. Comparable as a small-cap public pain company navigating hospital reimbursement and adoption.

Broad incumbents

• Vertex Pharmaceuticals: Vertex is developing VX-548, a non-opioid NaV1.8 inhibitor for acute pain, directly addressing the same postsurgical and acute pain opportunity that ATX-101 targets. While Vertex is a much larger diversified pharma, its pain program is a direct competitor in the same call point.
• Pfizer: Pfizer (via Hospira) manufactures and distributes generic bupivacaine, the active pharmaceutical in ATX-101, and has broad hospital channel reach. As the dominant generic local anesthetic supplier, Pfizer represents the pricing and incumbency backdrop against which ATX-101 must compete.
• Johnson & Johnson: J&J operates across orthopedic devices (DePuy Synthes, the largest orthopedic implant franchise that supplies TKAs) and has historical pharma involvement in pain. Highly relevant as the hospital channel partner that orthopedic surgeons already rely on for TKA implants.
• B. Braun Melsungen: B. Braun is a major manufacturer and global distributor of bupivacaine and other local anesthetics with deep hospital and surgery-center reach. Comparable as a broad-line incumbent local-anesthetic supplier against whom ATX-101 will compete on formulary.

Regional players

• Sintetica: Sintetica is a European specialty injectable and anesthetic manufacturer with a focus on hospital pain management including bupivacaine formulations. Comparable as a regional player developing and commercializing hospital-channel pain products analogous to ATX-101's target market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/allaytx
• LinkedInlinkedin.com/company/allaytx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allay Therapeutics